Clinical Trials on Hepatorenal Tyrosinemia

Total 69 results

CENTOGENE GmbH Rostock

Withdrawn

Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin) (BioTyrosin)

Metabolic Disorders | Tyrosinosis | Hepatorenal Tyrosinemia | Fumarylacetoacetase Deficiency | Fah Deficiency

Germany, Sri Lanka, India
Vitaflo International, Ltd

Completed

Evaluation of TYR Sphere

Alkaptonuria | Tyrosinemias | Tyrosinemia, Type I | Tyrosinemia, Type II | Tyrosinemia, Type III

United Kingdom
metaX Institut fuer Diatetik GmbH
Great Ormond Street Hospital for Children NHS Foundation Trust; Birmingham...

Not yet recruiting

Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies (ZeroMinisMR)

Alkaptonuria | Homocystine; Metabolic Disorder | Tyrosinemia, Type I | Tyrosinemia, Type II | Tyrosinemia, Type III | MSUD (Maple Syrup Urine Disease)
Yassin Abdelghaffar Charity Center for Liver Disease...
Society of Friends of Liver Patients in the Arab World (SLPAW)

Recruiting

Hereditary Hepatorenal Tyrosinemia Natural History in Egypt and the Arab World (Multicenter Clinical Study)

Hereditary Tyrosinemia, Type I

Egypt
Cycle Pharmaceuticals Ltd.
Parexel

Completed

Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)

Hereditary Tyrosinemia, Type I

South Africa
Swedish Orphan Biovitrum

Completed

Taste and Palatability of Orfadin Suspension

Hereditary Tyrosinemia, Type I

Germany, United Kingdom, France
Cycle Pharmaceuticals Ltd.
Parexel

Completed

Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin

Hereditary Tyrosinemia, Type I

South Africa
Swedish Orphan Biovitrum

Completed

Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1 (HT-1)

Hereditary Tyrosinemia, Type I

Belgium, Denmark, France, Germany, Sweden
Swedish Orphan Biovitrum

Completed

Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care (OPAL)

Hereditary Tyrosinemia, Type I

Belgium, Denmark, France, Germany, Austria, Czechia, Finland, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, United Kingdom
Cycle Pharmaceuticals Ltd.
Parexel

Completed

Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)

Hereditary Tyrosinemia, Type I

South Africa
University of Washington

Completed

Study of NTBC for Tyrosinemia I

Tyrosinemia I

United States, Canada
National Center for Research Resources (NCRR)
University of Michigan

Completed

Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I

Tyrosinemia, Type I
Swedish Orphan Biovitrum

Recruiting

A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

Hereditary Tyrosinemia, Type I

China
Vitaflo International, Ltd

Recruiting

Evaluation of the Express Plus Range (express plus)

Phenylketonurias | PKU | Maple Syrup Urine Disease | Homocystinuria | Glutaric Acidemia I | Hereditary Tyrosinemia

United Kingdom
Sutphin Drugs

Unknown

Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine (Orfadin)

Hereditary Tyrosinemia, Type I

India
Nutricia UK Ltd

Completed

GMP Case Studies of Tolerance, Safety and Acceptability in PKU and TYR

PKU | Tyrosinemias

United Kingdom
Vitaflo International, Ltd

Active, not recruiting

Evaluation of TYR Sphere in France (TYR sphere Fra)

Tyrosinemia | AKU

France
Medical University of Vienna

Completed

Plasma and Hemodynamic Markers During Hepatectomy

Hepatorenal Syndrome, Liver Regeneration

Austria
Ferring Pharmaceuticals

Completed

A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1 (HRS)

Hepatorenal Syndrome Type 1

Japan
Pere Gines

Unknown

Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response (AMELIORATE)

Cirrhosis | Hepatorenal Syndrome Type I

Spain
University of Alberta
Novartis

Completed

The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

Refractory Ascites | Type 2 Hepatorenal Syndrome

Canada
University of Padova

Unknown

Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome

Cirrhosis | Type 1 Hepatorenal Syndrome

Italy
La Jolla Pharmaceutical Company

Terminated

A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome

Hepatorenal Syndrome Type I and Type II

United States
National Hepatology & Tropical Medicine Research...

Completed

Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.

Renal Impairment in Hepatorenal Syndrome

Egypt
Hospices Civils de Lyon

Unknown

Automatic Segmentation of Polycystic Liver (ASEPOL)

Polycystic Liver Disease | Liver Injury | Polycystic Hepatorenal Disease

France
University of Pennsylvania

Active, not recruiting

Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) (INFUSE)

Hepatorenal Syndrome

United States
Mallinckrodt

Completed

Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

Hepatorenal Syndrome

United States, Canada
Patrick Northup, MD

Terminated

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

Hepatorenal Syndrome

United States
University of Louisville

Completed

Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg

Hepatorenal Syndrome

United States
The University of Hong Kong
The Hong Kong Society of Nephrology

Unknown

Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

Hepatorenal Syndrome

Hong Kong
Cumberland Pharmaceuticals

Completed

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Hepatorenal Syndrome

United States, India
Mallinckrodt

Completed

Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1

Hepatorenal Syndrome

United States
Institute of Liver and Biliary Sciences, India

Withdrawn

To Compare the Efficacy of Nor Adrenaline and Terlipressin vs Step up Terlipressin Therapy in Hepatorenal Syndrome

Hepatorenal Syndrome

India
Sun Yat-sen University

Unknown

The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure

Hepatorenal Syndrome

China
Anna Cruceta

Withdrawn

Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure

Fibrosis | Renal Failure | Hepatorenal Syndrome

Spain
Hospital Clinic of Barcelona

Completed

Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis

Hepatorenal Syndrome

Spain
National Hepatology & Tropical Medicine Research...

Completed

Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome

Hepato-Renal Syndrome

Egypt
Hospital Clinic of Barcelona
Grant from Education Ministery from 2001-2004.

Suspended

Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin

Cirrhosis | Hepatorenal Syndrome

Spain
Mallinckrodt

Completed

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

Hepatorenal Syndrome

United States, Canada
University of Turin, Italy

Completed

Noradrenalin vs Terlipressin in Hepatorenal Syndrome

Hepatorenal Syndrome

Italy
University of Padova

Terminated

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

Cirrhosis | Hepatorenal Syndrome

Italy
University Hospital, Bonn

Recruiting

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome (NECTAR)

Kidney Failure, Acute

Germany
Postgraduate Institute of Medical Education and...

Completed

Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1

Type 1 HEPATO RENAL SYNDROME(HRS)

India
University of Sao Paulo
Federal University of Rio Grande do Sul; University of Campinas, Brazil; Hospital... and other collaborators

Unknown

Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis

Acute Kidney Injury | Hepatorenal Syndrome

Brazil
Lahey Clinic
Beth Israel Deaconess Medical Center; Dr. Vikas Sukhatme

Terminated

Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome

Liver Diseases | Renal Failure | Hepatorenal Syndrome

United States
Samar Atef Sebaweh Mohammed

Completed

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

Ascites Infection

Egypt
Soonchunhyang University Hospital

Unknown

Korean Cohort Study of AKI & HRS in Cirrhosis

Liver Cirrhosis | Acute Kidney Injury | Hepatorenal Syndrome

Korea, Republic of
Hospital Clinic of Barcelona

Completed

Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis

Cirrhosis | Hepatorenal Syndrome | Spontaneous Bacterial Peritonitis

Spain
Hospices Civils de Lyon

Completed

Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury

Cirrhosis | Acute Kidney Injury | Hepatorenal Syndrome | Diastolic Function

France
Postgraduate Institute of Medical Education and...

Completed

TYPE 2 HEPATORENAL SYNDROME (Type2 HRS)

Safety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRS

India

Clinical Trials on Hepatorenal Tyrosinemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations